insitro Presents New Data Demonstrating Its AI-Discovered MASH Candidate Shows Anti-Fibrotic Signal Beyond Liver-Fat Reduction at the American Diabetes Associatio…

Findings from insitro’s lead therapeutic CTRO-1013 program demonstrate that liver-targeted silencing of IRS1 lowered ...
BioWorld

EA-3571, a dual inhibitor of enteropeptidase and trypsin with efficacy in mouse model of MASH

Recently presented preclinical data show that EA Pharma Co. Ltd.'s EA-3571 is a highly potent dual inhibitor of enteropeptidase and trypsin with luminal action, resulting in potential anti-insulin ...
BioWorld

New siRNA therapy candidate, ETX-312, shows efficacy in MASH mouse model

Researchers from E-Therapeutics plc presented preclinical data for ETX-312, a GalNAc-conjugated short interfering RNA (siRNA), produced using the Galomic platform and being developed for the treatment ...
EurekAlert!

Mouse models for the study of liver fibrosis regression in vivo and ex vivo

Liver fibrosis is a progressive and potentially reversible condition that results from chronic liver damage, which can be caused by a variety of factors, including metabolic dysfunction-associated ...